Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4256086 | 0.88 | CDK2 (0.32) | CDK2CCNA2CCNA1AURKAPDPK1 | |
| Trifluoroacetic Acid SCHEMBL1655186 | 0.88 | KDM4C (0.34) | CDK2NAMPTPDPK1 | |
| Trifluoroacetic Acid SCHEMBL6793561 | 0.88 | CDK2 (0.32) | CDK2CCNA2CCNA1AURKAPDPK1 | |
| SCHEMBL6794291 | 0.88 | NAMPT (0.34) | CDK2CCNA2CCNA1AURKANAMPT | |
| Trifluoroacetic Acid SCHEMBL4270585 | 0.87 | CDK2 (0.33) | CDK2CCNA2CCNA1AURKANAMPT | |
| Trifluoroacetic Acid SCHEMBL4263119 | 0.87 | ROCK2 (0.39) | CDK2CCNA2CCNA1AURKANAMPT | |
| Trifluoroacetic Acid SCHEMBL1656607 | 0.87 | CDK2 (0.36) | CDK2CCNA2CCNA1AURKANAMPT | |
| Trifluoroacetic Acid SCHEMBL4255932 | 0.86 | KDM4C (0.34) | CDK2NAMPTPDPK1 | |
| Trifluoroacetic Acid SCHEMBL1655450 | 0.86 | NAMPT (0.41) | CDK2CCNA2CCNA1AURKANAMPT | |
| Trifluoroacetic Acid SCHEMBL4263955 | 0.86 | ALDH1A1 (0.38) | CDK2CCNA2CCNA1AURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CDK2 29/4885CCNA2 270/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.